Health Care News – Read More An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight.  Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss.  The highest dose of retatrutide helped patients…